Anti Rh D Immunoglobulin 250 IU, 500IU, 1500IU Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 250 IU, 500IU, 1500IU

Reference Brands: RhoGAM (USA), HyperRho (EU/LATAM), Immunate-R (India)

Category: Plasma Products

Anti-D (Rh0) immunoglobulin prevents Rh-negative mothers from forming antibodies against Rh-positive fetal blood, protecting future pregnancies from haemolytic disease of the newborn. It is given around 28 weeks of pregnancy and after delivery or other sensitising events. Doses range from 250 to 1,500 IU; reference products include RhoGAM and Rhophylac. Ask PharmaTradz for a quote; we confirm the manufacturer, registration documents and lead time for your country.

Product Description:

When an Rh-negative mother is carrying an Rh-positive baby, the mother's antibodies cross the placenta and attacks the blood cells of the baby, resulting in haemolytic disease.

Rho(D) Immune Globulin (RhIG) is a plasma-derived immunoglobulin used primarily for the prevention of Rh isoimmunization in Rh-negative pregnant women and for the treatment of immune thrombocytopenic purpura (ITP). In Rh-negative pregnancies, RhIG provides passive immunity by neutralizing fetal Rh-positive red blood cells that may enter the maternal circulation, thereby preventing the maternal immune system from producing antibodies that could cause hemolytic disease of the newborn in current or future pregnancies. In ITP, RhIG helps increase platelet counts by modulating the immune response against platelets.

RhIG is prepared from human plasma containing high levels of anti-D antibodies, purified to ensure safety and efficacy. It is typically administered intramuscularly or intravenously, with the dose calculated based on maternal body weight or the clinical indication. Common adverse effects are mild and may include local pain, erythema, or low-grade fever. RhIG is contraindicated in individuals with a history of severe allergic reactions to immunoglobulin products or IgA deficiency with antibodies against IgA. Its rapid action, safety profile, and critical role in preventing hemolytic disease of the newborn make RhIG an essential therapy in maternal-fetal medicine and select hematologic conditions.